National Institutes of Biomedical Innovation; Health and Nutrition
发明人:
Ken Ishii,Etsushi Kuroda,Burcu Temizoz
申请号：
US15528002
公开号：
US20170319680A1
申请日:
2015.03.20
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.
